Can nicorandil be prescribed for myocardial bridging?

Can Nicorandil Be Used for Myocardial Bridging?

Yes, nicorandil can be prescribed for symptomatic myocardial bridging and appears to be a reasonable therapeutic option, particularly when beta-blockers or calcium channel blockers are not tolerated or are insufficient.

Evidence Supporting Nicorandil in Myocardial Bridging

The most direct evidence comes from a study demonstrating that intracoronary nicorandil dilates coronary arteries during both diastole and systole in patients with myocardial bridging 1. This is mechanistically important because:

• Nicorandil reduced the maximal diameter narrowing from 44.0% to 30.3% (p < 0.001)
• The minimal diameter during systole increased significantly from 1.24 mm to 1.67 mm (p < 0.001)
• In contrast, nitroglycerin actually worsened the percentage vessel narrowing from 44.9% to 56.0% (p = 0.023), confirming why pure nitrates should be avoided in myocardial bridging

This unique property distinguishes nicorandil from traditional nitrates—its dual mechanism as both a nitrate and potassium channel opener allows it to dilate the vessel during systolic compression, the critical pathophysiologic problem in myocardial bridging.

Guideline Context for Antianginal Use

While guidelines don't specifically address myocardial bridging, they provide a framework for nicorandil use in angina:

ESC Guidelines position nicorandil as:

• An alternative to beta-blockers when they cannot be tolerated (Class IIb, Level C) 2
• Add-on therapy when angina persists despite beta-blocker treatment (Class IIb, Level C) 2
• Important caveat: Safety in heart failure is uncertain, and it should not be combined with nitrates or used in triple therapy with ivabradine and ranolazine 2

The 2024 ESC Guidelines maintain that nicorandil "may be considered as add-on therapy in patients with inadequate control of symptoms while on treatment with beta-blockers and/or CCBs" (Class IIb, Level B) 3.

The 2006 ESC Guidelines specifically mention that "nicorandil, a potassium channel activator, may also be useful in occasional patients with refractory vasospastic angina" 4, which shares pathophysiologic similarities with myocardial bridging (dynamic vessel compression).

Clinical Approach to Myocardial Bridging

First-Line Treatment

Beta-blockers remain the preferred initial therapy because they:

• Reduce heart rate, prolonging diastolic filling time
• Decrease myocardial contractility, reducing systolic compression
• Have established safety profiles

Second-Line: Calcium Channel Blockers

Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) are the next step:

• Recent case reports demonstrate complete symptom resolution with diltiazem in symptomatic myocardial bridging 5
• They reduce heart rate and contractility without the paradoxical worsening seen with pure nitrates

Role of Nicorandil

Nicorandil should be considered when:

1. Beta-blockers are contraindicated or not tolerated
2. Calcium channel blockers are insufficient or contraindicated
3. As add-on therapy to beta-blockers or calcium channel blockers when symptoms persist

Dosing: Start with 5-10 mg twice daily, titrate to 20 mg twice daily as tolerated (based on angina studies) 6

Important Safety Considerations

Avoid in These Situations:

• Do NOT combine with long-acting nitrates (no additional efficacy and unknown safety) 2
• Do NOT use in triple therapy with ivabradine and ranolazine (unknown safety) 2
• Caution with aspirin: Concomitant use may increase risk of gastrointestinal ulcers, perforations, and hemorrhage 6
• Uncertain safety in heart failure 2

Common Adverse Effects:

• Headache (most common, may lead to discontinuation)
• Reflux, tachycardia, facial flushing, hypotension 6
• Rarely: serious skin, mucosal, and eye ulceration 6

Practical Algorithm for Myocardial Bridging

1. Confirm diagnosis: Coronary angiography showing systolic compression with normal diastolic filling
2. Start beta-blocker (e.g., metoprolol 25-50 mg twice daily, titrate up)
3. If inadequate response or intolerance: Add or switch to non-dihydropyridine CCB (diltiazem 30-60 mg three times daily, titrate up)
4. If still symptomatic: Consider adding nicorandil 5-10 mg twice daily, increase to 20 mg twice daily
5. Avoid sublingual nitroglycerin for acute symptoms (may worsen bridging); use short-acting beta-blockers instead if needed
6. Reserve surgical myotomy or stenting for refractory cases despite maximal medical therapy

Key Clinical Pitfall

Never use pure nitrates (nitroglycerin, isosorbide mononitrate/dinitrate) in myocardial bridging—they preferentially dilate the vessel during diastole while potentially worsening systolic compression, paradoxically increasing symptoms 1. Nicorandil's unique dual mechanism avoids this problem by also dilating during systole through potassium channel activation.